We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
Read MoreHide Full Article
Commercial-stage biopharmaceutical Omeros Corporation (OMER - Free Report) announced encouraging preliminary results from an early-stage study of its MASP-3 inhibitor, OMS906.
The ongoing phase I study is designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) and subcutaneous (SC) administration of OMS906 in healthy adult volunteers.
The phase I study design consists of both single- and multiple-ascending dose cohorts. OMS906, administered up to 5 mg/kg, was well tolerated at all IV and SC doses tested with no apparent safety signals. Single 3 mg/kg IV dose of OMS906 suppresses mature CFD below minimum detectable levels for 4 weeks. The single lowest SC dose of OMS906 suppresses mature CFD at or below minimum detectable levels for 4 weeks.
The dose-dependent PK/PD profile across all cohorts is favorable and supports low-dose, once-monthly or less frequent subcutaneous dosing.
We note that the study is ongoing with additional single- and multiple-dose cohorts to determine the pharmacologic dose range and optimal frequency for subcutaneous administration.
Omeros’ MASP-3 inhibitor program includes potent molecules selectively inhibiting mannan-binding lectin-associated serine protease-3 (MASP-3), the protein activator of the alternative pathway of complement (APC).
The preliminary data validate the function of MASP-3 — the key activator of the alternative pathway — as a regulator of CFD and support the potential of OMS906 as a safe and long-acting therapeutic for the treatment of alternative pathway-related diseases and disorders. The company intends to advance to a phase II study as soon as possible.
The development of the candidate will strengthen Omeros’ pipeline. The stock has increased 12.1% so far this year compared with the industry’s gain of 1.1%.
Image Source: Zacks Investment Research
The company’s lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement. The Biologics License Application (BLA) for narsoplimab is under priority review with the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
The company recently announced that the FDA will require additional time to review the BLA. The new target action date is Oct 17, 2021.
The BLA was accepted for filing in January 2021 under the FDA’s Priority Review program, with an action date of Jul 17, 2021. Omeros recently submitted a response to an FDA information request.
The agency has classified the response as a major amendment, which requires additional time to review as part of the ongoing BLA Priority Review. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19.
Meanwhile, its marketed drug, Omidria, continues to gain market share in cataract surgery.
Omeros currently carries a Zacks Rank #4 (Sell).
A few better-ranked stocks in the healthcare sector include Repligen Corp. (RGEN - Free Report) , Cumberland Pharmaceuticals Inc. (CPIX - Free Report) and Xencor, Inc. (XNCR - Free Report) , each carrying a Zacks Rank #2 (Buy).
Earnings estimates for Repligen for 2021 are up 40 cents.
Earnings estimates for Cumberland for 2021 are up 8 cents.
Loss estimates for Xencor have narrowed 81 cents.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Image: Bigstock
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
Commercial-stage biopharmaceutical Omeros Corporation (OMER - Free Report) announced encouraging preliminary results from an early-stage study of its MASP-3 inhibitor, OMS906.
The ongoing phase I study is designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) and subcutaneous (SC) administration of OMS906 in healthy adult volunteers.
The phase I study design consists of both single- and multiple-ascending dose cohorts. OMS906, administered up to 5 mg/kg, was well tolerated at all IV and SC doses tested with no apparent safety signals. Single 3 mg/kg IV dose of OMS906 suppresses mature CFD below minimum detectable levels for 4 weeks. The single lowest SC dose of OMS906 suppresses mature CFD at or below minimum detectable levels for 4 weeks.
The dose-dependent PK/PD profile across all cohorts is favorable and supports low-dose, once-monthly or less frequent subcutaneous dosing.
We note that the study is ongoing with additional single- and multiple-dose cohorts to determine the pharmacologic dose range and optimal frequency for subcutaneous administration.
Omeros’ MASP-3 inhibitor program includes potent molecules selectively inhibiting mannan-binding lectin-associated serine protease-3 (MASP-3), the protein activator of the alternative pathway of complement (APC).
The preliminary data validate the function of MASP-3 — the key activator of the alternative pathway — as a regulator of CFD and support the potential of OMS906 as a safe and long-acting therapeutic for the treatment of alternative pathway-related diseases and disorders. The company intends to advance to a phase II study as soon as possible.
The development of the candidate will strengthen Omeros’ pipeline. The stock has increased 12.1% so far this year compared with the industry’s gain of 1.1%.
The company’s lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement. The Biologics License Application (BLA) for narsoplimab is under priority review with the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
The company recently announced that the FDA will require additional time to review the BLA. The new target action date is Oct 17, 2021.
The BLA was accepted for filing in January 2021 under the FDA’s Priority Review program, with an action date of Jul 17, 2021. Omeros recently submitted a response to an FDA information request.
The agency has classified the response as a major amendment, which requires additional time to review as part of the ongoing BLA Priority Review. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19.
Meanwhile, its marketed drug, Omidria, continues to gain market share in cataract surgery.
Omeros currently carries a Zacks Rank #4 (Sell).
A few better-ranked stocks in the healthcare sector include Repligen Corp. (RGEN - Free Report) , Cumberland Pharmaceuticals Inc. (CPIX - Free Report) and Xencor, Inc. (XNCR - Free Report) , each carrying a Zacks Rank #2 (Buy).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Earnings estimates for Repligen for 2021 are up 40 cents.
Earnings estimates for Cumberland for 2021 are up 8 cents.
Loss estimates for Xencor have narrowed 81 cents.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>